Novo Nordisk shares fall after quarterly miss as Lilly rivalry intensifies
The Danish drugmaker's results fell short of expectations while Eli Lilly presses its advantage in the incretin market.
TR
By Tom Reyes · Markets Editor
Aug 4 03:00 ETSource: Investor's Business Daily
The wire
- 01Investor's Business Daily reports Novo Nordisk stock dropped after the company missed a key financial expectation in its latest quarterly results.
- 02Novo's semaglutide franchise underpins much of the branded GLP-1 supply clinicians and pharmacies rely on, so competitive pressure can shape pricing and access.
- 03The report does not detail which line items missed; readers should look to the full earnings statement and guidance for the operational picture.
From the source
Read at investors.comNovo Nordisk Stock Stumbles On A Key Miss As Its Battle With Eli Lilly Heats Up
